These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 1672668)
21. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Hudziak RM; Lewis GD; Winget M; Fendly BM; Shepard HM; Ullrich A Mol Cell Biol; 1989 Mar; 9(3):1165-72. PubMed ID: 2566907 [TBL] [Abstract][Full Text] [Related]
22. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells. Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001 [TBL] [Abstract][Full Text] [Related]
23. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy. Stancovski I; Peles E; Ben Levy R; Lemprecht R; Kelman Z; Goldman-Michael R; Hurwitz E; Bacus S; Sela M; Yarden Y J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):95-103. PubMed ID: 1356018 [TBL] [Abstract][Full Text] [Related]
24. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Park BW; Zhang HT; Wu C; Berezov A; Zhang X; Dua R; Wang Q; Kao G; O'Rourke DM; Greene MI; Murali R Nat Biotechnol; 2000 Feb; 18(2):194-8. PubMed ID: 10657127 [TBL] [Abstract][Full Text] [Related]
25. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187 [TBL] [Abstract][Full Text] [Related]
26. Biological effects of monoclonal antireceptor antibodies reactive with neu oncogene product, p185neu. Myers JN; Drebin JA; Wada T; Greene MI Methods Enzymol; 1991; 198():277-90. PubMed ID: 1677444 [No Abstract] [Full Text] [Related]
27. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Bargmann CI; Weinberg RA Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5394-8. PubMed ID: 2899890 [TBL] [Abstract][Full Text] [Related]
28. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins. Wada T; Myers JN; Kokai Y; Brown VI; Hamuro J; LeVea CM; Greene MI Oncogene; 1990 Apr; 5(4):489-95. PubMed ID: 1970151 [TBL] [Abstract][Full Text] [Related]
29. p185HER2 signal transduction in breast cancer cells. Scott GK; Dodson JM; Montgomery PA; Johnson RM; Sarup JC; Wong WL; Ullrich A; Shepard HM; Benz CC J Biol Chem; 1991 Aug; 266(22):14300-5. PubMed ID: 1677643 [TBL] [Abstract][Full Text] [Related]
30. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro. Cao H; Decker S; Stern DF Oncogene; 1991 May; 6(5):705-11. PubMed ID: 1675782 [TBL] [Abstract][Full Text] [Related]
31. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. Shalaby MR; Shepard HM; Presta L; Rodrigues ML; Beverley PC; Feldmann M; Carter P J Exp Med; 1992 Jan; 175(1):217-25. PubMed ID: 1346155 [TBL] [Abstract][Full Text] [Related]
32. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation. Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346 [TBL] [Abstract][Full Text] [Related]
33. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. McKenzie SJ; Marks PJ; Lam T; Morgan J; Panicali DL; Trimpe KL; Carney WP Oncogene; 1989 May; 4(5):543-8. PubMed ID: 2566965 [TBL] [Abstract][Full Text] [Related]
34. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. Fendly BM; Kotts C; Vetterlein D; Lewis GD; Winget M; Carver ME; Watson SR; Sarup J; Saks S; Ullrich A J Biol Response Mod; 1990 Oct; 9(5):449-55. PubMed ID: 1979347 [TBL] [Abstract][Full Text] [Related]
35. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. Dougall WC; Qian X; Greene MI J Cell Biochem; 1993 Sep; 53(1):61-73. PubMed ID: 7901229 [TBL] [Abstract][Full Text] [Related]
36. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Yarden Y Proc Natl Acad Sci U S A; 1990 Apr; 87(7):2569-73. PubMed ID: 1969636 [TBL] [Abstract][Full Text] [Related]
37. Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines. Kern JA; Robinson RA; Gazdar A; Torney L; Weiner DB Am J Respir Cell Mol Biol; 1992 Apr; 6(4):359-63. PubMed ID: 1312850 [TBL] [Abstract][Full Text] [Related]
38. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Modjtahedi H; Styles JM; Dean CJ Br J Cancer; 1993 Feb; 67(2):247-53. PubMed ID: 8094290 [TBL] [Abstract][Full Text] [Related]
39. Active c-erbB-2 induces short-term growth of FDC-P2 cells after IL-3 depletion. Wongsasant B; Matsuda S; Yamamoto T Biochem Biophys Res Commun; 1991 Dec; 181(3):981-8. PubMed ID: 1684897 [TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies to the amino-terminal sequence of the c-yes gene product as specific probes of its expression. Sukegawa J; Akatsuka T; Sugawara I; Mori S; Yamamoto T; Toyoshima K Oncogene; 1990 Apr; 5(4):611-4. PubMed ID: 2183163 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]